U.S. researchers found that allogeneic stem cell transplantation, which uses donor stem cells, was more effective than autologous cell transplantation and chemotherapy in improving survival and reducing the risk of relapse in patients with poor and intermediate risk of survival from acute myeloid leukemia. The study suggests that allogeneic transplant could be used as a standard treatment for most patients in the intermediate-risk group, one of the researchers said.

Full Story:

Related Summaries